<DOC>
	<DOCNO>NCT00406146</DOCNO>
	<brief_summary>Artemisinin combination therapy ( ACT ) currently recommend malaria treatment . Artemether-lumefantrine ( A-L ) Artesunate+amodiaquine ( A+A ) commonly adopt recommend ACT regimen . In Ghana , A+A current first-line antimalarial treatment Ghana , 1 efficacy report regimen Ghana till date . Moreover , safety repeat treatment ACT little studied . This study aim evaluate efficacy A+A vs. A-L , well safety repeat treatment regimens longitudinal trial recruit child follow 1 year .</brief_summary>
	<brief_title>Amodiaquine+Artesunate vs. Artemether-Lumefantrine Uncomplicated Malaria Ghanaian Children</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Amodiaquine , artesunate drug combination</mesh_term>
	<criteria>microscopically confirm acute uncomplicated falciparum malaria ; temperature screen 37.50C history fever 24 precede enrollment ; willingness comply follow schedule ; write informed consent accompany parent guardian feature severe malaria danger sign malaria know intolerance allergy study medication know treatment study medication month precede enrollment serious underlying disease may mask outcome assessment</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>November 2006</verification_date>
</DOC>